The interferon landscape along the respiratory tract impacts the severity of COVID-19

[1]  Guilin Wang,et al.  Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics , 2021, The Journal of experimental medicine.

[2]  Kenneth G. C. Smith,et al.  Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease , 2021, Immunity.

[3]  F. Granucci,et al.  Maturation signatures of conventional dendritic cell subtypes in COVID‐19 suggest direct viral sensing , 2021, European journal of immunology.

[4]  Mary K. Lewinski,et al.  Functional landscape of SARS-CoV-2 cellular restriction , 2021, Molecular Cell.

[5]  Michiel van Gent,et al.  ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity , 2021, Nature Microbiology.

[6]  C. Ziegler,et al.  Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19 , 2021, Cell.

[7]  B. Ye,et al.  SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO , 2021, Cell Reports.

[8]  J. Casanova,et al.  SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4 , 2021, The Journal of experimental medicine.

[9]  Chun Jimmie Ye,et al.  Global absence and targeting of protective immune states in severe COVID-19 , 2021, Nature.

[10]  Elizabeth B White,et al.  Diverse Functional Autoantibodies in Patients with COVID-19 , 2020, Nature.

[11]  N. Koulouris,et al.  Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison , 2020, Nature Immunology.

[12]  R. Webby,et al.  Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes , 2020, Cell.

[13]  R. Hotchkiss,et al.  Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm , 2020, Science Advances.

[14]  R. Webby,et al.  Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes , 2020, bioRxiv.

[15]  Chun Jimmie Ye,et al.  Global Absence and Targeting of Protective Immune States in Severe COVID-19 , 2020, bioRxiv.

[16]  M. Guttman,et al.  SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses , 2020, Cell.

[17]  Barbara B. Shih,et al.  Genetic mechanisms of critical illness in COVID-19 , 2020, Nature.

[18]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[19]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[20]  Vineet D. Menachery,et al.  Evasion of Type I Interferon by SARS-CoV-2 , 2020, Cell Reports.

[21]  M. Fukushi,et al.  SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant , 2020, Cell Reports.

[22]  S. Chanda,et al.  MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells , 2020, Cell Reports.

[23]  P. Shi,et al.  In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age , 2020, PLoS biology.

[24]  N. Koulouris,et al.  Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison , 2020, Nature Immunology.

[25]  J. Mason,et al.  A dynamic COVID-19 immune signature includes associations with poor prognosis , 2020, Nature Medicine.

[26]  Shamus P. Keeler,et al.  SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.

[27]  L. Ren,et al.  Activation and evasion of type I interferon responses by SARS-CoV-2 , 2020, Nature Communications.

[28]  Eric Song,et al.  Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.

[29]  S. Farhadian,et al.  Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection , 2020, medRxiv.

[30]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[31]  C. Dooms,et al.  Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages , 2020, Cell Research.

[32]  Inkyung Jung,et al.  Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19 , 2020, Science Immunology.

[33]  K. Bhaskaran,et al.  OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.

[34]  Bryan D. Bryson,et al.  Dissecting the common and compartment-specific features of COVID-19 severity in the lung and periphery with single-cell resolution , 2020, bioRxiv.

[35]  Akiko Iwasaki,et al.  Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19 , 2020, Cell Host & Microbe.

[36]  M. Llorian,et al.  Type I and III interferons disrupt lung epithelial repair during recovery from viral infection , 2020, Science.

[37]  F. Granucci,et al.  Type III interferons disrupt the lung epithelial barrier upon viral recognition , 2020, Science.

[38]  Jie Dong,et al.  Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients , 2020, Cell Host & Microbe.

[39]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[40]  L. Prokunina-Olsson,et al.  COVID-19 and emerging viral infections: The case for interferon lambda , 2020, The Journal of experimental medicine.

[41]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[42]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[43]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[44]  F. Granucci,et al.  Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion , 2019, The Journal of experimental medicine.

[45]  Gennady Korotkevich,et al.  Fast gene set enrichment analysis , 2019, bioRxiv.

[46]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[47]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..